Oncology (all articles)
SR | Partial breast irradiation for breast cancer
3 Feb, 2023 | 14:06h | UTCPartial Breast Irradiation for Breast Cancer – Agency for Healthcare Research and Quality
RCT | First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma
3 Feb, 2023 | 14:02h | UTC
M-A | Treatment- and immune-related AEs of checkpoint inhibitors in esophageal or gastroesophageal junction cancer
3 Feb, 2023 | 13:55h | UTC
M-A | Major complications and mortality after resection of intrahepatic cholangiocarcinoma
3 Feb, 2023 | 13:43h | UTC
M-A | Risk of non-hormonal cancer after bariatric surgery
2 Feb, 2023 | 14:37h | UTCRisk of non-hormonal cancer after bariatric surgery: meta-analysis of retrospective observational studies – British Journal of Surgery (link to abstract – $ for full-text)
Commentary: Bariatric Surgery May Reduce the Risk of Some Common Cancers – National Cancer Institute
M-A | Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer
2 Feb, 2023 | 14:36h | UTC
Preliminary study suggests chemotherapy delivery in the afternoon may improve outcomes in patients with DLBC lymphoma
1 Feb, 2023 | 13:27h | UTCCommentaries:
Chemotherapy schedule affects treatment outcomes in female DLBCL patients – News Medical
SR | Immediate breast reconstruction uptake in older women with primary breast cancer
1 Feb, 2023 | 13:04h | UTC
M-A | Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma
31 Jan, 2023 | 13:42h | UTC
SR | There is insufficient evidence to recommend corticosteroids for the management of cancer‐related fatigue
30 Jan, 2023 | 00:47h | UTC
RCT | Adjuvant temozolomide with or without interferon alfa in patients with newly diagnosed high-grade gliomas
30 Jan, 2023 | 00:27h | UTCCommentary: Interferon Alfa Improves Upon Standard Care in High Grade Glioma – Cancer Therapy Advisor
Commentary on Twitter
This phase 3 clinical trial demonstrated interferon alfa + temozolomide prolonged survival time in patients with newly diagnosed high-grade gliomas by median 8 months (18% vs 9% 5yr overall survival), especially with MGMT promoter unmethylated tumors. https://t.co/2yOssnF97G
— JAMA Network Open (@JAMANetworkOpen) January 27, 2023
Cohort Study | Risk of malignant neoplasms of the gastrointestinal tract after blood or marrow transplant
30 Jan, 2023 | 00:23h | UTCMalignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation – The ASCO Post
Commentary on Twitter
Exposure to cytarabine, etoposide and anthracyclines & chronic graft vs. host disease increase risk of colorectal, liver & esophageal cancer after BMT, providing evidence for appropriate evaluation & management in high-risk populations. https://t.co/UENFM1UWRw
— JAMA Oncology (@JAMAOnc) January 23, 2023
Salivary gland cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
27 Jan, 2023 | 12:16h | UTC
M-A | Sensitivity and complications of thoracentesis and thoracoscopy for the diagnosis of malignant pleural effusions
27 Jan, 2023 | 12:11h | UTC
Diagnostic Study | Usefulness of CT radiomics in differentiating histologic subtypes of epithelial ovarian carcinoma
27 Jan, 2023 | 12:01h | UTC
Commentary on Twitter
Radiomic features extracted from contrast-enhanced CT scans were useful in the classification of histologic subtypes in epithelial ovarian carcinoma, high-grade serous carcinoma (HGSC) and non-HGSC. https://t.co/DBAXnl9r0X #OAResearch
— JAMA Network Open (@JAMANetworkOpen) December 6, 2022
M-A | Proximal gastrectomy with double-tract-reconstruction vs. total gastrectomy in gastric and gastroesophageal junction cancer patients
27 Jan, 2023 | 11:54h | UTC
Pre-existing autoimmune disease increases the risk of cardiovascular and noncardiovascular events after immunotherapy
26 Jan, 2023 | 12:09h | UTC
Review | Lung cancer screening: new evidence, updated guidance
26 Jan, 2023 | 12:08h | UTCLung cancer screening: New evidence, updated guidance – Journal of Family Practice
Perspective | Endocrine treatment for 5 years or radiation for 5 days for patients with early breast cancer older than 65 years
26 Jan, 2023 | 12:04h | UTC
Commentary from the author on Twitter
🚨Hot off the press @JCO_ASCO: For decades we have been offering RT omission for early #bcsm patients, here we discuss how tides have changed and its time to omit hormonal therapy and treat with RT instead @TaghianAlphonse @MGHBreastOnc @LurieCancer
— George E. Naoum, MD, MMSCI (@George_E_Naoum) December 20, 2022
RCT | Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion
26 Jan, 2023 | 12:03h | UTC
RCT | Preoperative chemotherapy reduced recurrence in operable colon cancer
25 Jan, 2023 | 11:29h | UTCEditorial: FOxTROT: Are We Ready to Dance? – Journal of Clinical Oncology
News Release: Chemotherapy before surgery cuts risk of colon cancer returning, trial finds – Cancer Research UK
Commentary: New treatment strategy cuts risk of bowel cancer returning by 28% – The Guardian
Commentary from one of the authors on Twitter (thread – click for more)
🥁🥁🥁Tweetorial
FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer
We report that NAC is
✅deliverable and safe
✅led to statistically significant reduction in cancer recurrence than upfront surgery
A 🧵 (1/14)#crcsmhttps://t.co/y1hU6qWdXF— Jenny Seligmann (@JenSeligmann) January 20, 2023
Consensus Paper | Tumor surveillance guidelines for individuals with neurofibromatosis type 1
25 Jan, 2023 | 11:24h | UTC
Single-arm phase 2 study | Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors
24 Jan, 2023 | 14:19h | UTCNeoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Neoadjuvant Pembrolizumab in Localized MSI-H/dMMR Solid Tumors – The ASCO Post
RCT | Breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection vs. standard surgical treatment of axilla
24 Jan, 2023 | 14:15h | UTC
Commentary on Twitter
New & available #OpenAccess | Occurrence of breast-cancer–related #lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial https://t.co/fXB7PfysCH @OncoAlert pic.twitter.com/wWNhC9BMvY
— ACS Journal Cancer (@JournalCancer) October 20, 2022
Meta-analysis reaffirms benefits of O-RADS MRI for diagnosing indeterminate adnexal lesions
24 Jan, 2023 | 14:05h | UTCOriginal Study: O-RADS MRI: A Systematic Review and Meta-Analysis of Diagnostic Performance and Category-wise Malignancy Rates – Radiology (link to abstract – $ for full-text)
Commentary on Twitter
A meta-analysis of 4520 adnexal lesions from 12 studies showed that MRI O-RADS has a 92% summary sensitivity and a 91% summary specificity in characterizing lesions that are indeterminate at US. https://t.co/WSJVQUiM4T pic.twitter.com/kssAK2s02N
— Radiology (@radiology_rsna) November 23, 2022